1. Introduction {#sec1-molecules-23-02696}
===============

Drug-metabolizing enzymes can be categorized into two groups which are Phase I and Phase II enzymes. A compound can be metabolized either during one of the phases or both to be excreted out from the body. Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are the major Phase II metabolizing enzymes responsible for the reaction known as glucuronidation \[[@B1-molecules-23-02696]\]. The glucuronidated metabolites have higher polarity and water solubility making them easily excreted by urine and bile. According to the review by Wells et al. \[[@B2-molecules-23-02696]\] in humans approximately 40--70% of clinical drugs are metabolized through this pathway. Nevertheless, endobiotics such as bilirubin, steroids, retinoids and bile acids also undergo this route of detoxification \[[@B3-molecules-23-02696]\].

UGT2B7 appears to be a very important human UGT isoform. Drugs that have been identified to be metabolized by this isoform are the opioids such as codeine, morphine and oxycodone \[[@B4-molecules-23-02696],[@B5-molecules-23-02696]\], the non-steroidal anti-inflammatory drugs (NSAIDs) including diclofenac, niflumic acid and mefanamic acid \[[@B6-molecules-23-02696]\], the anticonvulsant valproic acid \[[@B7-molecules-23-02696]\] and zidovudine, the therapeutic agent used in HIV treatment \[[@B8-molecules-23-02696]\]. Additionally, harmful non-drug xenobiotics such as 2-acetylaminofluorene and benzo\[α\]pyrene to which humans might be exposed through inhalation or dermal contact also undergo glucuronidation via UGT2B7 to be eliminated from the body \[[@B9-molecules-23-02696]\].

Herbal medicines have been used to treat various ailments and diseases since millennia. Nowadays, herbal medicines are taken as complementary and/or alternative medicines (CAMs) by people around the world, especially by the patients with chronic diseases such as diabetes, cancer, and human immunodeficiency virus (HIV) \[[@B10-molecules-23-02696],[@B11-molecules-23-02696],[@B12-molecules-23-02696]\]. Furthermore, a study indicates that CAM therapies are mostly taken as complementary medicines along with conventional medicines rather than as alternatives medicines \[[@B13-molecules-23-02696]\]. Concurrent consumption of herbs and drugs raises the concern about interactions between herbs and drugs \[[@B14-molecules-23-02696]\]. Herbal medicines contain numerous bioactive constituents which are responsible for their therapeutic effects. These herbal constituents might share the same metabolic pathway with the drug, therefore, inhibition of the drug-metabolizing enzyme activity may decrease the drug's metabolic clearance and increase its level in the body which in turn may lead to toxicity. A recent study reported that sauchinone, an active principle of the herb *Saururus chinensis* elevated the zidovudine (ZDV) concentration in mice blood by inhibiting UGT2B7 activity \[[@B15-molecules-23-02696]\]. This can cause haematological toxicity \[[@B16-molecules-23-02696]\]. Another study revealed that curcumin from *Curcuma* species \[[@B17-molecules-23-02696]\] inhibited UGT2B7 in vitro \[[@B18-molecules-23-02696],[@B19-molecules-23-02696]\].

All this suggests that determination of the causative herbal constituent(s) of herb-drug interactions associated with UGT2B7 is required as many important drugs are metabolized by the enzyme. In this study, 13 bioactive herbal constituents were investigated for their inhibitory effects on UGT2B7 in HLM and RLM. [Table 1](#molecules-23-02696-t001){ref-type="table"} summarizes the effect of the constituents on UGT isoform activities in the literature. Based on the table, the in vitro inhibition of arecaidine, arecoline, (+)-catechin, gallic acid, kaempferol-3-rutinoside, quercetin, vanillin, vitexin, isovitexin and zerumbone on UGT2B7 has not been reported. Meanwhile, the effects of andrographolide, mangiferin and mitragynine against the activity of UGT2B7 have been previously screened in vitro. However, no study on andrographolide's effect in RLM has been published. There is also no reported data on the effect of mangiferin and mitragynine on UGT2B7 in both HLM and RLM.

ZDV was used as the probe substrate to determine the UGT2B7 isoform activity in the current study. ZDV glucuronide formed was analyzed using a modified and validated high performance liquid chromatography (HPLC) method. Meanwhile, human and rat liver microsomes were used to investigate interspecies differences, as rats are the most common animals utilized pre-clinical in vivo studies. Data generated in this study will provide useful information for researchers with an intention to carry out further in vivo study in rats and humans as well as to provide a better understanding of the risks associated with the concomitant use of herbal medicines with pharmaceutical drugs among the general public including healthcare professionals.

2. Results {#sec2-molecules-23-02696}
==========

2.1. HPLC Method Validation {#sec2dot1-molecules-23-02696}
---------------------------

An HPLC method to quantify zidovudine glucuronide (ZDVG) in liver microsomes was validated in terms of specificity, linearity, sensitivity, precision, accuracy, extraction recovery and matrix effect according to the US Food and Drug Administration (FDA) \[[@B41-molecules-23-02696]\] and International Conference on Harmonisation (ICH) \[[@B42-molecules-23-02696]\].

### 2.1.1. Specificity {#sec2dot1dot1-molecules-23-02696}

The peaks of ZDVG, ZDV and the internal standard, 4-methylumbelliferone glucuronide (4MUG), eluted at retention times of 7.9, 9.9 and 13.1 min, respectively, without overlapping. The specificity of this proposed analytical method was determined by the absence of endogenous interferences at the retention times of peaks of interest which were ZDVG and 4MUG. The chromatograms in [Figure 1](#molecules-23-02696-f001){ref-type="fig"} show that there were no interferences from the endogenous substances on the retention times of both peaks.

### 2.1.2. Linearity and Sensitivity {#sec2dot1dot2-molecules-23-02696}

The calibration curve of the ratio of ZDVG/4MUG peak areas against ZDVG concentration was linear, with the regression equation y = 0.0811x − 0.0098 and a correlation coefficient of 0.9998. Meanwhile, the limits of detection (LOD) and quantification (LOQ) of ZDVG were 0.5 μM and 1.5 μM respectively.

### 2.1.3. Precision and Accuracy {#sec2dot1dot3-molecules-23-02696}

The precision and accuracy for intra- and inter-day of the method were determined with LOD and quality control (QC) samples of ZDVG at concentrations of 1.5, 4.5, 12.5 and 22.5 µM. The data is tabulated in [Table 2](#molecules-23-02696-t002){ref-type="table"}.

The intra-day precision ranged from 0.78% to 2.18% and the accuracy ranged from −4.39% to 8.58%. For inter-day assessment, precision ranged from 1.68% to 2.96% while accuracy ranged from −1.03% to 7.94%. All observed data were less than ±15% for QC samples and ±20% for the LOQ sample as suggested by the FDA \[[@B41-molecules-23-02696]\].

### 2.1.4. Extraction Recovery and Matrix Effect {#sec2dot1dot4-molecules-23-02696}

Determinations of extraction recovery and matrix effect were conducted to measure the effectiveness of the sample preparation to generate values close to the actual sample values without any extraction and matrix influences. QC samples were used to evaluate both factors. The extraction recovery of ZDVG in HLM incubation assay after centrifugation was 101.25%, 98.55% and 97.69% for the low, medium and high QC samples, respectively. No significant matrix effect towards ZDVG was observed as well. Recovery of ZDVG from matrix effect was more than 96% for all QC samples. [Table 3](#molecules-23-02696-t003){ref-type="table"} shows the recovery obtained for both factors.

2.2. Zidovudine (ZDV) Glucuronidation in HLM {#sec2dot2-molecules-23-02696}
--------------------------------------------

### 2.2.1. Optimization of HLM and RLM Incubation Condition {#sec2dot2dot1-molecules-23-02696}

Latency of UGT2B7 enzyme activity in HLM and RLM was removed using 0.1 mg/mg of polyethylene glycol hexadecyl ether (Brij58). Following that, an addition of 1% (*w*/*v*) of bovine serum albumin (BSA) into the HLM and RLM incubation mixtures increased ZDVG formation by 4-fold and 2.5-fold, respectively, compared to the one without BSA ([Figure 2](#molecules-23-02696-f002){ref-type="fig"}). Moreover, formation of ZDVG with HLM was linear with protein concentration (up to 0.5 mg/mL) at an incubation time of 120 min and linear with time (up to 180 min) at a HLM concentration of 0.2 mg/mL. Meanwhile, formation of ZDVG with RLM was linear with protein concentration (up to 6 mg/mL) at an incubation time of 90 min and incubation time (up to 180 min) at RLM concentration of 2 mg/mL.

### 2.2.2. ZDV Glucuronidation Kinetics in HLM and RLM {#sec2dot2dot2-molecules-23-02696}

ZDV glucuronidation kinetics in HLM and RLM were evaluated in the absence and presence of 1% (*w*/*v*) BSA ([Figure 3](#molecules-23-02696-f003){ref-type="fig"}). The addition of 1% (*w*/*v*) BSA in HLM and RLM incubation assays did not affect the maximal velocity (V~max~) value significantly. However, the Michaelis constant (K~m~) value was decreased approximately 4-fold and 2.5-fold for HLM and RLM incubation assays respectively compared to the assays without BSA. This condition results in a corresponding increase in the intrinsic clearance (CL~int~) of ZDV in both HLM and RLM. These kinetic data are shown in [Table 4](#molecules-23-02696-t004){ref-type="table"}.

### 2.2.3. Inhibition Studies of Herbal Bioactive Constituents on ZDV Glucuronidation in HLM {#sec2dot2dot3-molecules-23-02696}

The inhibitory potential of the herbal constituents on ZDV glucuronidation was evaluated using three different concentrations for each constituent which were 1 µM, 10 µM and 100 µM. Among them, andrographolide, kaempferol-3-rutinoside, mitragynine and zerumbone had shown 50% inhibition at concentration below 100 µM ([Figure 4](#molecules-23-02696-f004){ref-type="fig"}). These four constituents were then further evaluated to determine their precise half-maximal inhibitory concentration (IC~50~) using additional concentration points. The IC~50~s obtained for andrographolide, kaempferol-3-rutinoside, mitragynine and zerumbone were 6.18 ± 1.27 μM, 18.56 ± 8.62 μM, 8.11 ± 4.48 μM and 4.57 ± 0.23 μM, respectively. The IC~50~ plots are illustrated in [Figure 5](#molecules-23-02696-f005){ref-type="fig"}.

### 2.2.4. Inhibition Studies of Herbal Bioactive Constituents on ZDV Glucuronidation in RLM {#sec2dot2dot4-molecules-23-02696}

The inhibitory potential of the thirteen herbal bioactive constituents on ZDV glucuronidation in RLM was evaluated similarly as in HLM. In RLM, only mitragynine and zerumbone had inhibited ZDV glucuronidation higher than 50% at concentration below 100 µM ([Figure 6](#molecules-23-02696-f006){ref-type="fig"}). The result of precise IC~50~ values show that mitragynine and zerumbone exhibited inhibition on ZDV glucuronidation in RLM with IC~50~ values of 51.20 ± 5.95 µM and 8.14 ± 2.12 µM respectively. The IC~50~ plots for both constituents are shown in [Figure 7](#molecules-23-02696-f007){ref-type="fig"}.

3. Discussion {#sec3-molecules-23-02696}
=============

An optimized and validated HPLC-UV method was successfully applied to the determination of ZDV glucuronidation activity in liver microsomes. Thirteen herbal bioactive constituents including andrographolide, arecaidine, arecoline, (+)-catechin, gallic acid, kaempferol-3-rutinoside, mangiferin, mitragynine, quercetin, vanillin, vitexin, isovitexin and zerumbone were studied to determine their inhibitory potential on ZDV glucuronidation in HLM and RLM.

Prior to the inhibition study, an optimized ZDV incubation assay in HLM and RLM had been established under a steady state condition where the metabolites formed were not more than 30% formed \[[@B43-molecules-23-02696]\] and were linearly correlated with protein concentration and incubation time. Meeting these requirements allows the straightforward data interpretation as the reversible reaction between the substrate and the product formed will not take place \[[@B44-molecules-23-02696]\]. Latency of UGT2B7 enzyme in microsomes also had been removed using an optimum Brij58 concentration. In addition, an addition of 1% (*w*/*v*) BSA content into the incubation mixture of HLM and RLM also had reduced the K~m~ value of ZDV without significantly affecting its V~max~ value as shown in [Table 3](#molecules-23-02696-t003){ref-type="table"}. V~max~ is the maximal velocity of the enzymatic reaction whilst K~m~ or Michaelis constant is the substrate concentration at half of V~max~. The reduction of K~m~ value is consistent with previous studies \[[@B45-molecules-23-02696],[@B46-molecules-23-02696]\] although we had used a lower BSA content. It is postulated that BSA sequesters the fatty acids released during the course of microsomal incubation in which these fatty acids have been reported to be inhibitors of UGT2B7 enzyme \[[@B46-molecules-23-02696]\].

K~m~ and V~max~ values with inclusion of 1% of BSA for HLM are 0.88 ± 0.05 mM and 1450 ± 26.06 pmol/mg/min, respectively, whereas for RLM, they are 6.77 ± 0.60 mM and 1089 ± 33.50 pmol/mg/min, respectively. The K~m~ value in RLM is almost 8-fold higher when compared to HLM. However, the V~max~ value of ZDV glucuronidation in RLM is not significantly different from the one obtained in HLM. This trend is much easier to see when the liver microsomal intrinsic clearance (CL~int~) of ZDV glucuronidation is determined in both HLM and RLM. Fundamentally, CL~int~ is defined as the ability of the liver to metabolize the drug in the absence of flow limitations and binding to cells or proteins in the blood. The in vitro CL~int~ may be derived from the enzymes kinetic data which is V~max~/K~m~ \[[@B47-molecules-23-02696],[@B48-molecules-23-02696]\]. Therefore, the CL~int~ in HLM is 1.65 µL/mg/min whereas in RLM it is 0.16 µL/mg/min. There is a 10-fold difference of CL~int~ value between HLM and RLM. Furthermore, it has been reported that approximately 75% and 10% of a ZDV dose were excreted as glucuronides in humans \[[@B49-molecules-23-02696]\] and rats \[[@B50-molecules-23-02696]\], respectively. Consequently, the in vivo systemic clearance of ZDV in humans was estimated to be 1.01 L/h/kg for 70 kg of man \[[@B51-molecules-23-02696]\] which is almost 6-fold greater than the systemic clearance in rats which is 0.18 L/h/kg for 0.25 kg of rat \[[@B50-molecules-23-02696],[@B52-molecules-23-02696]\]. Thus, it might be concluded that the capability of rats to metabolize ZDV is weaker compared to humans.

The inhibition study in HLM showed that four out of thirteen herbal bioactive constituents (andrographolide, kaempferol-3-rutinoside, mitragynine and zerumbone) inhibited ZDV glucuronidation activity. Andrographolide is a major constituent isolated from the herbal plant *Andrographis paniculata* (Burm. f.). A literature survey shows a wide spectrum of pharmacological significance of *A. paniculata* and andrographolide, including hepatoprotective, hypoglycaemic, cardioprotective, anti-inflammatory, immune stimulatory, anti-cancer, anti-HIV and antimalarial activities \[[@B53-molecules-23-02696],[@B54-molecules-23-02696]\]. Andrographolide was found to inhibit UGT2B7 enzyme activity in previous studies \[[@B19-molecules-23-02696],[@B20-molecules-23-02696],[@B22-molecules-23-02696],[@B23-molecules-23-02696]\]. Ma et al., reported that andrographolide non-competitively inhibited ZDV glucuronidation in HLM with an inhibition constant (K~i~) value of 6.1 µM \[[@B23-molecules-23-02696]\]. As IC~50~ = K~i~ for non-competitive inhibition mechanism \[[@B55-molecules-23-02696]\], therefore, the IC~50~ of their study can be deduced to be equal to the K~i~ value. Our study found a comparable IC~50~ value of 6.18 ± 1.27 µM. However in our previous study, andrographolide had shown weak inhibition in HLM when 4-methylumbelliferone (4MU) was used as a substrate \[[@B24-molecules-23-02696]\]. This could be because 4MU is a nonspecific UGT substrate which is mainly conjugated by UGT1A6 in humans and rats \[[@B56-molecules-23-02696]\], unlike ZDV which is a specific and selective substrate of UGT2B7 \[[@B57-molecules-23-02696]\]. This selectivity factor might be the reason for the differences in the observed results.

In order to interpret herb-drug interactions in vivo, the in vitro IC~50~ value obtained should be viewed as the in vivo concentration \[[@B27-molecules-23-02696]\]. Therefore, the in vivo inhibition potential of andrographolide in human liver can be estimated by comparing its IC~50~ value with its bioavailability in human plasma. A previous study \[[@B58-molecules-23-02696]\] showed that the maximum plasma concentration of andrographolide in humans after oral administration of 20 mg of andrographolide four times a day was 1.34 µg/mL (3.8 µM). The value is lower than the IC~50~ value of 6.18 µM obtained in this study. Another two pharmacokinetic studies of andrographolide showed that its maximum concentration in plasma were 58.6 ng/mL (0.17 µM) and 32.41 ng/mL (0.09 µM) after ingestion of 200 mg and 32.64 mg of andrographolide for three times a day, respectively \[[@B59-molecules-23-02696],[@B60-molecules-23-02696]\]. As the andrographolide concentration in plasma reportedly ranged from 0.09 to 3.8 µM which is less than the obtained IC~50~ value in HLM (6.18 ± 1.27 µM), inhibition of hepatic systemic clearance of UGT2B7 substrates in humans seems implausible.

In spite of that, due to first pass metabolism, orally administered drugs may be metabolized by the small intestine prior to their entrance into the liver \[[@B61-molecules-23-02696]\]. Based on estimates of intestinal volume that range from approximately 0.5 to 5 L anticipating a 100% bioavailability, minor protein binding and minor accumulation of the substances \[[@B62-molecules-23-02696]\], the intestinal concentration of the herbal constituents after their ingestion can also be predicted and compared with the hepatic IC~50~ value obtained in this study. Thus, following consumption of 20 to 200 mg of andrographolide, the expected intestinal concentration of andrographolide is 4 μg/mL (11.4 μM) and 400 μg/mL (1141 μM). These concentrations are higher than the IC~50~ for UGT2B7 inhibition by andrographolide in HLM. Thus, it is postulated that inhibition of intestinal glucuronidation of UGT2B7 substrates by andrographolide may be possible. Furthermore, UGT2B7 is also expressed in the human small intestine \[[@B63-molecules-23-02696]\].

This study has also shown mitragynine to have a strong inhibition towards ZDV glucuronidation in HLM with an IC~50~ value of 8.11 ± 4.48 μM. This IC~50~ value is lower than the IC~50~ value obtained previously with 4MU in HLM. Previously, mitragynine at a concentration of 1 μM inhibited 4MU glucuronidation in HLM by approximately 30% of control activity with an IC~50~ value higher than 1000 μM \[[@B37-molecules-23-02696]\]. This difference might be due to the non-specificity of 4MU as a substrate on UGT isoforms as aforementioned. Mitragynine may be a specific UGT2B7 inhibitor, however, further study on its inhibition mechanism needs to be carried out for confirmation.

Briefly, mitragynine is a major constituent of *Mitragyna speciosa*, a herbal plant with opium-like effects and coca-like simulative ability \[[@B64-molecules-23-02696],[@B65-molecules-23-02696]\]. Due to this, *M. speciosa* has been widely taken to alleviate opioid withdrawal symptoms \[[@B66-molecules-23-02696],[@B67-molecules-23-02696]\]. In addition, *M. speciosa* is also commonly consumed in combination with other drugs of abuse such as codeine or diphenhydramine cough syrup, amphetamine, ketamine, antidepressants drugs and opioids to achieve an intense feeling of pleasure \[[@B68-molecules-23-02696],[@B69-molecules-23-02696]\]. Opioids such as codeine, morphine and oxycodone are known to be metabolized by UGT2B7 \[[@B5-molecules-23-02696]\] whereas ketamine had been shown to inhibit UGT2B7 in vitro \[[@B37-molecules-23-02696],[@B70-molecules-23-02696]\].

Reported concentrations of mitragynine in postmortem blood samples ranged from 230 μg/L (0.58 µM) \[[@B71-molecules-23-02696]\] to 1006 μg/L (2.52 µM) \[[@B72-molecules-23-02696]\]. Meanwhile, a study conducted in humans showed that the maximum plasma concentration of mitragynine was 0.105 µg/mL (0.26 µM) following the ingestion of a *M. speciosa* tea containing 11 mg mitragynine for seven days followed by 23 mg of mitragynine on the eighth day \[[@B73-molecules-23-02696]\]. Since the plasma level of mitragynine is less than the observed IC~50~ of mitragynine obtained in this study which is 8.11 ± 4.48 µM, it is predicted that inhibition of systemic clearance of UGT2B7 substrates by mitragynine is unlikely to occur. In contrast, intestinal concentrations of mitragynine are expected to fall in the range of 4.6 mg/L (11.5 µM) to 553 mg/L (1388 µM) following the consumption of *M. speciosa* juice/tea containing 23 to 276.5 mg mitragynine \[[@B73-molecules-23-02696],[@B74-molecules-23-02696]\]. Therefore, mitragynine may inhibit the intestinal glucuronidation of UGT2B7 substrates when they are concomitantly consumed.

Kaempferol-3-rutinoside is a naturally derived flavonoid that is found in almost all herbal, as well as in vegetables and fruits. Flavonoids have been reported to possess a broad spectrum of health benefits due to their antioxidative, anti-inflammatory, anti-allergic, anti-mutagenic and anticancer properties, which are widely utilized in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications \[[@B75-molecules-23-02696]\]. Similar to andrographolide and mitragynine, kaempferol-3-rutinoside did not significantly inhibit UGT enzymes in HLM when 4MU was used as a substrate \[[@B24-molecules-23-02696]\]. On the other hand, it had inhibited UGT2B7-catalyzed glucuronidation of ZDV in HLM with an IC~50~ value of 18.56 ± 8.62 µM in this study. Since the magnitude is modest, herb-drug interaction involving this constituent is unlikely to occur. Furthermore, there is no data of kaempferol-3-rutinoside plasma concentration in humans to be compared with the obtained IC~50~ value. The daily recommended allowance (RDA) of kaempferol-3-rutinoside is also unavailable to estimate its intestinal concentration.

Zerumbone is a bioactive compound which is found in many species of the Zingiberaceae family such as *Zingiber zerumbet*, *Zingiber amaricans* and *Zingiber aromaticum*, although most abundantly in *Z. zerumbet* \[[@B76-molecules-23-02696]\]. Zerumbone has been described to be a promising drug for the treatment of different types of cancer such as colon, breast, cervix and liver cancer \[[@B76-molecules-23-02696]\]. There are limited studies regarding zerumbone metabolism and pharmacokinetics. Zerumbone does not have the common nucleophilic functional groups like aliphatic alcohols, phenols, carboxylic acids, thiols or aromatic and aliphatic amines to form glucuronides \[[@B77-molecules-23-02696],[@B78-molecules-23-02696]\]. However, a C-linked glucuronide can be formed at its acidic carbon atom (C-9 as shown in [Figure 8](#molecules-23-02696-f008){ref-type="fig"}). Moreover, glucuronidation of zerumbone may also take place on its carbonyl group in which the group is tautomerized into an enol group prior to the conjugation which consequently produces the zerumbone *O*-glucuronide \[[@B79-molecules-23-02696]\].

In terms of its effect on drug metabolizing enzyme activity, zerumbone had been shown to induce the Phase II gluthathione-S-transferases enzyme \[[@B80-molecules-23-02696]\] and moderately inhibit metabolism mediated by CYP3A4 \[[@B81-molecules-23-02696]\] in vitro. However, there is no published data for zerumbone effect on UGT enzymes. This study may be the first to report on zerumbone potently inhibiting ZDV glucuronidation in HLM with an IC~50~ value of 4.57 ± 0.23 µM. Unfortunately, zerumbone concentration in human plasma and its RDA were unavailable to be compared with the IC~50~ value obtained.

The inhibitory potency of the thirteen constituents investigated in HLM was also studied in RLM. Overall, the inhibition trend in RLM was similar to the trend in HLM for most constituents, only differing in their magnitude. Out of the four herbal constituents that had strongly inhibited ZDV glucuronidation in HLM, only two showed a similar magnitude of inhibition in RLM. These constituents were mitragynine and zerumbone, with IC~50~ values of 51.20 ± 5.95 µM and 8.14 ± 2.12 µM, respectively. The only constituent that showed a different trend in this study was andrographolide which strongly inhibited ZDV glucuronidation in HLM but showed weak inhibition in RLM. This may be due to the orthologous nature of the UGT2B7 enzyme. It is known that UGT2B1, an orthologous enzyme to UGT2B7 is expressed in rats instead of UGT2B7 itself. UGT2B1 does not always catalyze the same compounds as UGT2B7 \[[@B3-molecules-23-02696]\] even though it has been described to catalyze the same classes of substances as UGT2B7 \[[@B82-molecules-23-02696]\].

To the best of our knowledge, no study of andrographolide inhibition on UGT enzymes specifically UGT2B7 in RLM has been published. Nonetheless, a recent study conducted by Tian et al. described that when andrographolide was used as a substrate, it was glucuronidated in HLM but not in RLM \[[@B83-molecules-23-02696]\].

4. Materials and Methods {#sec4-molecules-23-02696}
========================

4.1. Chemical and Reagents {#sec4dot1-molecules-23-02696}
--------------------------

3′-Azido-3′-deoxythymidine (ZDV), 4-MU β-[d]{.smallcaps}-glucuronide hydrate (4MUG), andrographolide, arecaidine hydrochloride, arecoline hydrobromide, diclofenac (sodium salt), kaempferol-3-*O*-rutinoside, gallic acid, quercetin, mangiferin, zerumbone, bovine serum albumin (BSA), polyethylene glycol hexadecyl ether (Brij58), uridine 5′-diphosphoglucuronic acid trisodium salt (UDPGA), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) and magnesium chloride (MgCl~2~) and pooled human liver microsomes (Product No. M0567) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 3′-Azido-3′-deoxythymidine β-[d]{.smallcaps}-glucuronide sodium salt (ZDVG) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). (+)-Catechin hydrate and mitragynine were purchased from Chromadex (Irvine, CA, USA). Vitexin and isovitexin were obtained from Carl Roth GmbH (Karlsruhe, Germany). Vanillin was purchased from BDH chemicals Ltd. (Poole, UK). Potassium chloride (KCl) was obtained from Bendosen Laboratory Chemicals (Selangor, Malaysia). Sodium carbonate (Na~2~CO~3~), sodium hydroxide (NaOH), glycerol and potassium dihydrogen phosphate (KH~2~PO~4~) were obtained from Systerm^®^ (Shah Alam, Malaysia). Dipotassium hydrogen phosphate (K~2~HPO~4~) was obtained from Riedel-de Hӓen (Seelze, Germany). Folin and Ciocalteu's reagent and triethylamine were obtained from R&M Marketing (Essex, UK). Acetonitrile (HPLC grade) and absolute ethanol (analytical grade) were obtained from RCl Labscan Limited (Bangkok, Thailand). Dimethyl sulfoxide (DMSO) and formic acid HPLC grade (99.5%) were obtained from Fisher Scientific (Loughborough, UK).

4.2. Animals {#sec4dot2-molecules-23-02696}
------------

Six male Sprague Dawley rats (150--200 g) were obtained from Animal House, Universiti Sains Malaysia (USM). The rats were placed under 12 h light and 12 h dark conditions with controlled temperature (25 ± 2 °C) for seven days before the start of the experiments. Water and food *ad libitium* were provided to the rats. The animals were maintained and handled according to the recommendations of the USM ethical committee which approved the animal experiments with reference number of USM/Animal Ethics Approval/2013/(90) (527). The livers were taken out from the rats after sacrificing them by cervical dislocation for microsomes preparation.

4.3. Rat Liver Microsomes Preparation {#sec4dot3-molecules-23-02696}
-------------------------------------

The livers were rinsed promptly with ice-cold distilled water followed by ice-cooled 67 mM potassium phosphate buffer (pH 7.4) containing 1.15% (*w*/*v*) KCl after removal from the rats. The livers were then homogenized in three volumes of the same buffer using Potter-Elvehjem homogenizer after blotted dry and weighed. After that, the homogenate was centrifuged at 12,500× *g* for 20 min at 4 °C. The resultant supernatant was further centrifuged at 100,000× *g* for 60 min at 4 °C to obtain the microsomal pellets. Each pellet obtained was scrapped and reconstituted in 0.3 mL of 67 mM potassium phosphate buffer with 1.15% (*w*/*v*) KCl and 20% (*v*/*v*) glycerol before homogenizing them together to obtain pooled microsomes. Microsomes were then transferred into several microfuge tubes and stored at −80 °C until used.

4.4. Instrumentation and Chromatographic Conditions {#sec4dot4-molecules-23-02696}
---------------------------------------------------

HPLC was performed using a Jasco HPLC system with intelligent UV/Vis detector (Jasco International Co., Ltd., Tokyo, Japan) fitted with a reversed phase Hypersil Gold C18 column (150 × 4.6 mm I.D., 5 µm particle size; Thermo Fisher Scientific, Waltham, MA, USA). The optimized method used the isocratic mobile phase consisting of 0.5% formic acid in deionized water and acetonitrile (90:10%; *v*/*v*) which ran at 1.0 mL/min for 15 min. A sample of 10 µL injection volume was monitored at 267 nm wavelength.

4.5. Validation of HPLC Method for Quantification of ZDVG {#sec4dot5-molecules-23-02696}
---------------------------------------------------------

The HPLC method was validated for specificity, linearity, sensitivity, precision, accuracy, extraction recovery and matrix effect according to the guidelines issued by FDA \[[@B41-molecules-23-02696]\] and International Conference on Harmonisation (ICH) \[[@B42-molecules-23-02696]\].

### 4.5.1. Specificity {#sec4dot5dot1-molecules-23-02696}

Specificity was determined by analyzing a HLM incubation sample to evaluate for any endogenous interferences at retention times of ZDVG and 4MUG (IS). A comparison study was conducted on chromatograms of a blank HLM incubation matrix sample, HLM incubation sample without UDPGA, and HLM incubation sample with UDPGA. Blank sample spiked with pure standards of ZDVG, ZDV and 4MUG served as reference.

### 4.5.2. Linearity {#sec4dot5dot2-molecules-23-02696}

The linearity of the developed HPLC method was evaluated by a calibration curve constructed using six different concentrations of ZDVG at 1.5, 3, 5, 10, 15, and 30 µM spiked in incubation buffer. The reading for each concentration was taken for three different days with five replicates per day. A total of fifteen replicates (*n* = 15) for each concentration were used to construct the curve. The peak area ratios of ZDVG and 4MUG (IS) were plotted against the nominal concentrations of ZDVG spiked in incubation buffer.

### 4.5.3. Sensitivity {#sec4dot5dot3-molecules-23-02696}

Sensitivity of HPLC method was evaluated by determining the limits of detection (LOD) and quantification (LOQ) using data generated from the calibration curve. LOD and LOQ were calculated as LOD = 3.3 (SD~y-int~/S) and LOQ = 10 (SD~y-int~/S). SD~y-int~ is standard deviation of y-intercept and S is the slope of the calibration curve.

### 4.5.4. Precision and Accuracy {#sec4dot5dot4-molecules-23-02696}

Precision and accuracy were determined using LOQ and quality control (QC) samples at concentrations 1.5, 4.5, 12.5 and 22.5 μM of ZDVG spiked in incubation buffer. Intra- and inter-day precision and accuracy were assessed by analyzing LOQ and QC samples in five replicates on the same day and over three consecutive days, respectively. Precision was expressed as percent coefficient of variance (% CV) whilst accuracy was expressed as percent relative mean error (% RME). CV (%) and RME (%) were calculated as follows: CV (%) = (standard deviation/mean) × 100; RME (%) = (\[measured concentration − nominal concentration\]/\[nominal concentration\]) × 100.

### 4.5.5. Extraction Recovery and Matrix Effect {#sec4dot5dot5-molecules-23-02696}

Five replicates of QC samples were used to evaluate extraction recovery of ZDVG and matrix effect on ZDVG. Extraction recovery was calculated by comparing the analytical response of ZDVG spiked pre-centrifugation to the one spiked post-centrifugation. The matrix effect was evaluated by comparing the analytical response of ZDVG spiked post-centrifugation to the one spiked directly into distilled water. In this experiment, the analytical response measured was the mean of peak area ratio of ZDVG/4MUG.

4.6. Microsomal Incubation Assay {#sec4dot6-molecules-23-02696}
--------------------------------

An incubation mixture in a total volume of 200 µL contained 100 mM Tris-HCl buffer at pH 7.4, 5 mM MgCl~2~, microsomal protein (0.2 mg/mL for HLM assay and 2 mg/mL for RLM assay) and 0.1 mg/mg protein of Brij58 was kept in ice for 10 min. After that, ZDV (concentration at or below the K~m~ value) and 1% (*w*/*v*) of bovine serum albumin (BSA) were added into the incubation mixture. The incubation volume was made up to 200 µL with distilled water in a 1.5 mL polypropylene microcentrifuge tube. After pre-incubation at 37 °C for 10 min in a shaking water bath, a reaction was started by the addition of 5 mM UDPGA and was further incubated (120 min for HLM and 90 min for RLM). Following the incubation, the reaction was terminated by adding 100 µL ice-cold acetonitrile containing 75 µM of 4MUG as the internal standard (IS). The sample was allowed for protein precipitation on ice for 15 min, then vortexed shortly, and centrifuged at 15,000 rpm for 10 min at 4 °C. Supernatant was transferred into HPLC vials for HPLC analysis.

4.7. Optimization of Incubation Conditions {#sec4dot7-molecules-23-02696}
------------------------------------------

Preliminary assays in terms of optimization of Brij58 concentration, BSA content and linearity of microsomal protein concentration as well as incubation time were performed to ensure ZDV glucuronidation experiments were carried out under initial linear velocity condition (product formation \< 30%). Brij58 concentration was optimized at concentration ranged from 0--0.4 mg/mg of protein. Optimization of BSA concentration ranged from 0--0.2% (*w*/*v*) in the presence of optimized Brij58 concentration in the incubation assay was then carried out. After that, the linearity of protein concentration and incubation time with ZDVG formation was assessed with the inclusion of the optimized concentration of Brij58 and BSA.

4.8. Enzyme Kinetics of ZDV Glucuronidation {#sec4dot8-molecules-23-02696}
-------------------------------------------

Once the initial velocity conditions had been established, the ZDV concentrations were varied to generate a saturation curve for determination of Michaelis constant (K~m~) and maximal velocity of reaction (V~max~) values of ZDV glucuronidation in HLM and RLM. The experiments were conducted in the absence and presence of BSA. Under optimized conditions, substrate concentrations used in incubation assay were varied from 0--5 mM of ZDV for HLM assay and 0--30 mM of ZDV for RLM assay. All assays were performed in triplicates (*n* = 3). The enzyme kinetic parameters (K~m~ and V~max~) were obtained by fitting kinetic models to the experimental data using GraphPad Prism version 5.01 for Windows.

4.9. Preparation of Potential Inhibitors Solution {#sec4dot9-molecules-23-02696}
-------------------------------------------------

Stock solutions for the herbal constituents were prepared at concentrations of 50 mM by dissolving them in their respective solvents. Andrographolide, arecoline, arecaidine, mangiferin and vanillin were dissolved in distilled water. (+)-Catechin, mitragynine and gallic acid were dissolved in ethanol. Meanwhile, kaempferol-3-rutinoside, quercetin, vitexin, isovitexin and zerumbone were dissolved in dimethyl sulfoxide (DMSO). Working solutions were prepared at concentrations of 5 mM in distilled water so that the final organic solvent concentrations in incubations were less than 2% (*v*/*v*).

4.10. Inhibition Study of ZDV Glucuronidation in HLM and RLM {#sec4dot10-molecules-23-02696}
------------------------------------------------------------

Thirteen herbal constituents were screened for inhibition of ZDV glucuronidation in HLM and RLM. Screening experiments using three concentrations (1 µM, 10 µM and 100 µM) of each herbal constituent were conducted to screen for the inhibitory potential of the constituent. All incubation assays were performed in triplicate (*n* = 3). Constituents that showed at least 50% inhibition on ZDV glucuronidation at concentrations below 100 µM, was further studied using several concentrations to obtain the precise IC~50~ value.

4.11. Data Analysis {#sec4dot11-molecules-23-02696}
-------------------

The ZDVG concentration formed was quantified using the calibration curve of ZDVG. Final UGT2B7 specific activity value was expressed in pmol/min/mg protein. However, UGT2B7 specific activity was reported as the percentage of control activity (%) by comparing the UGT2B7 specific activity in the presence of the inhibitor to the one without inhibitor (control). IC~50~ value point where the enzyme activity was reduced by half was found graphically on the basis of the plot created using GraphPad Prism 5.0.1 for Windows (GraphPad Software, La Jolla, CA, USA) under dose--response inhibition (log \[inhibitor\] vs. normalized response \-- variable slope) model. K~m~ and V~max~ were determined using the same software under the enzyme-kinetic inhibition (substrate inhibition) model.

5. Conclusions {#sec5-molecules-23-02696}
==============

In summary, our study of the inhibitory potential of thirteen herbal bioactive constituents showed that andrographolide, kaemperol-3-rutinoside, mitragynine and zerumbone inhibit ZDV glucuronidation in HLM whilst only mitragynine and zerumbone inhibited ZDV glucuronidation in RLM. Hence, herb-drug interactions are a possibility if drugs that are highly metabolized by UGT2B7 are taken concomitantly with andrographolide, kaempferol-3-rutinoside, mitragynine and zerumbone. Herb-herb interactions may also occur if a herbal medicine consisting of a mixture of the herbal constituents is consumed. However, in order to confirm this finding, a clinical study needs to be conducted. In addition, due to the differences in the inhibitory outcomes in HLM and RLM, data for UGT2B7 inhibition in rats need to be extrapolated with caution to humans.
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![Representative chromatograms detected at λ = 267 nm. (**A**) a solution containing a mixture of zidovudine glucuronide (ZDVG), zidovudine (ZDV) and internal standard, 4-methylumbelliferone glucuronide (4MUG) at concentration of 150 μM. ZDVG, ZDV and 4MUG were eluted at 7.9, 9.9 and 13.1 min, respectively; (**B**) a HLM incubation matrix solution. No peaks were detected; (**C**) a HLM incubation assay in the absence of UDPGA. No metabolite (ZDVG) peak was detected whilst 4MUG was eluted at 13.1 min; (**D**) a HLM incubation assay in the presence of UDPGA. ZDVG and 4MUG were detected at 7.9 min and 13.1 min. (1) ZDVG; (2) ZDV; (3) 4MUG.](molecules-23-02696-g001){#molecules-23-02696-f001}

![Optimization of (**A**) bovine serum albumin (BSA) and (**B**) polyethylene glycol hexadecyl ether (Brij58) concentration in incubation with human (HLM) and rat liver microsomes (RLM). Each point represents the mean of zidovudine glucuronides (ZDVG) formation rate ± standard deviation (SD) for triplicates (*n* = 3).](molecules-23-02696-g002){#molecules-23-02696-f002}

![Michaelis-Menten plots for zidovudine (ZDV) glucuronidation catalyzed by (**A**) human liver microsomes (HLM) and (**B**) rat liver microsomes (RLM) with and without 1% (*w*/*v*) of bovine serum abumin (BSA). Each point represents the mean of zidovudine glucuronides (ZDVG) formation rate ± standard deviation (SD) for triplicates (*n* = 3).](molecules-23-02696-g003){#molecules-23-02696-f003}

![The screening of herbal bioactive constituents on zidovudine (ZDV) glucuronidation in human liver microsomes (HLM). Panels above show concentrations of the inhibitors used. Each bar represents the mean percentage activity relative to control ± standard deviation (SD) for triplicates (*n* = 3).](molecules-23-02696-g004){#molecules-23-02696-f004}

###### 

The inhibitory effect of (**A**) andrographolide, (**B**) kaempferol-3-rutinoside, (**C**) mitragynine and (**D**) zerumbone on zidovudine (ZDV) glucuronidation in human liver microsomes (HLM). Each point represents the mean percentage of relative ZDV-UGT2B7 specific activity over control ± standard deviation (SD) for triplicates (*n* = 3). Data points were fitted to non-linear regression (curve fit) using GraphPad Prism 5.01 to determine an IC~50~ value. Goodness of fit *R*^2^ values were greater than 0.9.

![](molecules-23-02696-g005a)

![](molecules-23-02696-g005b)

![The screening of herbal bioactive constituents on zidovudine (ZDV) glucuronidation in rat liver microsomes (RLM). Panels above show concentrations of the inhibitors used. Each bar represents the mean percentage activity relative to control ± standard deviation (SD) for triplicates (*n* = 3).](molecules-23-02696-g006){#molecules-23-02696-f006}

![The inhibitory effect of (**A**) mitragynine and (**B**) zerumbone on zidovudine (ZDV) glucuronidation in rat liver microsomes (RLM). Each point represents the mean percentage of relative ZDV-UGT2B7 specific activity over control ± standard deviation (SD) for triplicates (*n* = 3). Data points were fitted to non-linear regression (curve fit) using GraphPad Prism 5.01 to determine an IC~50~ value. Goodness of fit *R*^2^ values were greater than 0.9.](molecules-23-02696-g007){#molecules-23-02696-f007}

![Chemical structures of inhibitory herbal bioactive constituents on UGT2B7 enzyme.](molecules-23-02696-g008){#molecules-23-02696-f008}

molecules-23-02696-t001_Table 1

###### 

The effect of selected herbal constituents on UDP-glucuronosyltransferase (UGT) isoforms activities.

                                                                      Herbal Constituent        In Vitro Study                                                In Vivo/Ex Vivo Study      References
  ------------------------------------------------------------------- ------------------------- ------------------------------------------------------------- -------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.                                                                 Andrographolide           UGT nonspecific ![](molecules-23-02696-i001.jpg) (HLM)        UGT nonspecific ↑ (rats)   \[[@B19-molecules-23-02696],[@B20-molecules-23-02696],[@B21-molecules-23-02696],[@B22-molecules-23-02696],[@B23-molecules-23-02696],[@B24-molecules-23-02696]\]
  UGT1A3 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A4 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A6 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A7 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A8 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A9 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A10 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                  
  UGT2B4 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT2B7 ↓ (HLM, supersomes)                                                                                                                                                             
  2\.                                                                 Arecaidine                \-                                                            \-                         
  3\.                                                                 Arecoline                 UGT nonspecific ![](molecules-23-02696-i001.jpg) (RLM)        \-                         \[[@B25-molecules-23-02696]\]
  4\.                                                                 (+)-Catechin              \-                                                            \-                         
  5\.                                                                 Kaempferol                UGT nonspecific ↓ (HLM)                                       UGT1A1 ↑ (mice)            \[[@B26-molecules-23-02696],[@B27-molecules-23-02696],[@B28-molecules-23-02696],[@B29-molecules-23-02696],[@B30-molecules-23-02696]\]
  UGT nonspecific ↑ (mammalian cells)                                                                                                                                                    
  UGT1A1 ↓ (supersomes)                                                                                                                                                                  
  UGT1A1 ↑ (mammalian cells)                                                                                                                                                             
  UGT1A1 ↑ (mammalian cells)                                                                                                                                                             
  UGT1A3 ↓ (supersomes)                                                                                                                                                                  
  UGT1A6 ↓ (supersomes)                                                                                                                                                                  
  UGT1A9 ↓ (HLM, HIM, supersomes)                                                                                                                                                        
  UGT2B7 ↓ (supersomes)                                                                                                                                                                  
  UGT2B10 ↓ (supersomes)                                                                                                                                                                 
                                                                      Kaempferol-3-rutinoside   UGT nonspecific ![](molecules-23-02696-i001.jpg) (HLM)                                   \[[@B24-molecules-23-02696]\]
  6\.                                                                 Gallic acid               UGT2B17 ![](molecules-23-02696-i001.jpg) (supersomes)         \-                         \[[@B31-molecules-23-02696]\]
  7\.                                                                 Mangiferin                UGT1A1 ![](molecules-23-02696-i001.jpg) (hepatocytes)         \-                         \[[@B32-molecules-23-02696],[@B33-molecules-23-02696],[@B34-molecules-23-02696]\]
  UGT1A3 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A6 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A7 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A8 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A9 ![](molecules-23-02696-i001.jpg) (hepatocytes, supersomes)                                                                                                                      
  UGT1A10 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                  
  UGT2B4 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT2B7 ![](molecules-23-02696-i001.jpg) (hepatocytes, supersomes)                                                                                                                      
  UGT2B15 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                  
  UGT2B17 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                  
  8\.                                                                 Mitragynine               UGT nonspecific ![](molecules-23-02696-i001.jpg) (HLM, RLM)   UGT nonspecific ↑ (rats)   \[[@B35-molecules-23-02696],[@B36-molecules-23-02696],[@B37-molecules-23-02696]\]
  UGT1A1 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT2B7 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  9\.                                                                 Quercetin                 UGT nonspecific ↑ (mammalian cells)                           UGT nonspecific ↑ (rat)    \[[@B26-molecules-23-02696],[@B27-molecules-23-02696],[@B29-molecules-23-02696],[@B31-molecules-23-02696],[@B38-molecules-23-02696],[@B39-molecules-23-02696]\]
  UGT1A1 ↑ (mammalian cells)                                                                                                                                                             
  UGT1A1 ↓ (supersomes)                                                                                                                                                                  
  UGT1A3 ↓ (supersomes)                                                                                                                                                                  
  UGT1A4 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A6 ↑ (mammalian cells)                                                                                                                                                             
  UGT1A6 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                   
  UGT1A9 ↓ (HLM, RLM, supersomes)                                                                                                                                                        
  UGT2B10 ![](molecules-23-02696-i001.jpg) (supersomes)                                                                                                                                  
  UGT2B17 ↓ (supersomes)                                                                                                                                                                 
  10\.                                                                Vanillin                  UGT nonspecific ↓                                             \-                         \[[@B40-molecules-23-02696]\]
  11\.                                                                Vitexin                   UGT nonspecific ![](molecules-23-02696-i001.jpg) (HLM)        \-                         \[[@B24-molecules-23-02696]\]
  12\.                                                                Isovitexin                UGT nonspecific ![](molecules-23-02696-i001.jpg) (HLM)        \-                         \[[@B24-molecules-23-02696]\]
  13\.                                                                Zerumbone                 \-                                                            \-                         \-

↓, inhibition of enzyme activity; ↑, activation of enzyme activity; ![](molecules-23-02696-i001.jpg), weak inhibition or no effect on enzyme activity; HLM, human liver microsomes; RLM, rat liver microsomes.

molecules-23-02696-t002_Table 2

###### 

Intra- and inter-day precision (% CV) and accuracy (% RME) of zidovudine glucuronides (ZDVG). Measurements were taken for five replicates per day for three days.

  Calibrator (ZDVG)      Concentration (μM)   CV (%)   RME (%)   
  ---------------------- -------------------- -------- --------- -------
  Intra-day (*n* = 5)                                            
  LOQ                    1.5                  1.63     2.18      8.56
  QC1                    4.5                  4.55     1.67      1.06
  QC2                    12.5                 12.23    2.27      −2.17
  QC3                    22.5                 21.51    0.78      −4.39
  Inter-day (*n* = 15)                                           
  LOQ                    1.5                  1.62     1.68      7.94
  QC1                    4.5                  4.59     1.60      2.06
  QC2                    12.5                 12.37    2.84      −1.03
  QC3                    22.5                 22.29    2.96      −0.92

LOQ = limit of quantification; QC = quality control; CV = coefficient of variance; RME = relative mean error.

molecules-23-02696-t003_Table 3

###### 

Extraction recovery and matrix effect of zidovudine glucuronides (ZDVG). Measurement was made from five independent experiments (*n* = 5).

  ZDVG Calibrators                           QC1      QC2      QC3
  ------------------------------------------ -------- -------- --------
  ZDVG spiked sample ^1^                                       
  In incubation matrix pre-centrifugation    0.3697   0.9717   1.7869
  In incubation matrix post-centrifugation   0.3651   0.9860   1.8291
  In distilled water                         0.3665   1.0250   1.7996
  Extraction recovery (%)                    101.25   98.55    97.69
  Matrix Effect (%)                          99.64    96.19    101.64

^1^ Data represents the mean peak area ratio of ZDVG/4MUG; QC = quality control.

molecules-23-02696-t004_Table 4

###### 

Derived kinetic constants for zidovudine glucuronidation in human (HLM) and rat liver microsomes (RLM) obtained from the incubation with and without 1% (*w*/*v*) bovine serum albumin (BSA). Data are presented as mean ± SD.

            Without 1% BSA         With 1% BSA                                                              
  --------- ---------------------- ------------- --------------------- ---------------------- ------------- ---------------------
            V~max~ (pmol/mg/min)   K~m~ (mM)     CL~int~ (µL/mg/min)   V~max~ (pmol/mg/min)   K~m~ (mM)     CL~int~ (µL/mg/min)
  **HLM**   1092 ± 19.10           3.40 ± 0.70   0.32                  1450 ± 26.05           0.88 ± 0.05   1.65
  **RLM**   770 ± 39.82            8.84 ± 1.19   0.09                  1089 ± 33.50           6.77 ± 0.60   0.16

V~max~ = maximal velocity; K~m~ = Michaelis constant; CL~int~ = intrinsic clearance.
